|ZFIN ID: ZDB-PUB-160227-2|
Your Input Welcome
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.
Hypoxia as a therapy for mitochondrial disease
Jain, I.H., Zazzeron, L., Goli, R., Alexa, K., Schatzman-Bone, S., Dhillon, H., Goldberger, O., Peng, J., Shalem, O., Sanjana, N.E., Zhang, F., Goessling, W., Zapol, W.M., Mootha, V.K.
|Source:||Science (New York, N.Y.) 352(6281): 54-61 (Journal)|
|Registered Authors:||Goessling, Wolfram, Schatzman-Bone, Steph|
|PubMed:||26917594 Full text @ Science|
Jain, I.H., Zazzeron, L., Goli, R., Alexa, K., Schatzman-Bone, S., Dhillon, H., Goldberger, O., Peng, J., Shalem, O., Sanjana, N.E., Zhang, F., Goessling, W., Zapol, W.M., Mootha, V.K. (2016) Hypoxia as a therapy for mitochondrial disease. Science (New York, N.Y.). 352(6281):54-61.
ABSTRACTDefects in the mitochondrial respiratory chain (RC) underlie a spectrum of human conditions, ranging from devastating inborn errors of metabolism to aging. We performed a genome-wide, Cas9-mediated screen to identify factors that are protective during RC. inhibition. Our results highlight the hypoxia response, an endogenous program evolved to adapt to limiting oxygen availability. Genetic or small molecule activation of the hypoxia response is protective against mitochondrial toxicity in cultured cells and zebrafish models. Chronic hypoxia leads to a marked improvement in survival, body weight, body temperature, behavior, neuropathology and disease biomarkers in a genetic mouse model of Leigh syndrome, the most common pediatric manifestation of mitochondrial disease. Further preclinical studies are required to assess whether hypoxic exposure can be developed into a safe and effective treatment for human diseases associated with mitochondrial dysfunction.